OTC · Healthcare
Vireo Growth Inc. (VREOF)
As-reported financials and recent SEC filings for Vireo Growth Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$268.8M
Net income
$-68.1M
Net margin
-25.3%
Diluted EPS
$-0.09
ROE
-22.2%
P/E (TTM)
—
Market cap
—
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $268.8M | $99.4M | $88.1M | $74.6M | $54.4M |
| Gross profit | — | — | — | $35.2M | $22.4M |
| Operating income | $-1.0M | $13.6M | $10.6M | $-6.9M | $-20.5M |
| Net income | $-68.1M | $-28.0M | $-25.5M | $-42.5M | $-33.7M |
| Diluted EPS | $-0.09 | $-0.04 | $-0.05 | $-0.08 | $-0.07 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
D2026-06-22
View on EDGAR →8-K/A2026-06-18
View on EDGAR →8-K2026-06-18
View on EDGAR →8-K/A2026-06-11
View on EDGAR →8-K2026-06-11
View on EDGAR →8-K2026-06-11
View on EDGAR →8-K2026-06-09
View on EDGAR →32026-06-08
View on EDGAR →Go deeper on VREOF
Search Vireo Growth Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.